{
    "clinical_study": {
        "@rank": "166381", 
        "arm_group": [
            {
                "arm_group_label": "PF-04958242", 
                "arm_group_type": "Experimental", 
                "description": "PF-04958242 and ketamine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo and ketamine"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal\n      learning and memory, episodic memory and spatial working memory in healthy volunteers."
        }, 
        "brief_title": "A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": [
                "Schizophrenia", 
                "Cognition Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects 21 - 45 years old.\n\n          -  Able to read and write English as primary language.\n\n          -  Subjects who are willing to comply with study procedures.\n\n        Exclusion Criteria:\n\n          -  History of any substance abuse or dependence disorder meeting DSM-IV criteria and/or\n             by SCID-NP within the past 12 months, with the exception of nicotine.\n\n          -  Known sensitivity to ketamine\n\n          -  Any history of DSM-IV Axis I psychiatric disorders, determined by SCID-NP interview\n             or diagnoses in the view of the investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749098", 
            "org_study_id": "B1701013"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-04958242", 
                "description": "PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5", 
                "intervention_name": "PF-04958242", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-04958242", 
                "description": "At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo capsule orally administered on Days 1 - 5", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-04958242", 
            "ketamine", 
            "cognition", 
            "healthy volunteers"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1701013&StudyName=A%20Study%20To%20Examine%20The%20Effects%20Of%20PF-04958242%20On%20Ketamine-Induced%20Cognitive%20Impairment%20In%20Healthy%20Volunteers"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06516"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Test score on the Hopkins Verbal Learning Test - Immediate Recall", 
            "safety_issue": "No", 
            "time_frame": "Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749098"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Test score on the Weschler Digit Span Test", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Test score on the CogState N-back test", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Test score on the CogState Spatial Working memory test", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Test score on the CogState One Card Learning test", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Test score on the Hopkins Verbal Learning test - Delayed Recall", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Retrospective rating on the Positive and Negative Syndrome Scale -modified scale`", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}